MX2016006561A - Anticuerpo anti-calicreina-2 humanizado. - Google Patents

Anticuerpo anti-calicreina-2 humanizado.

Info

Publication number
MX2016006561A
MX2016006561A MX2016006561A MX2016006561A MX2016006561A MX 2016006561 A MX2016006561 A MX 2016006561A MX 2016006561 A MX2016006561 A MX 2016006561A MX 2016006561 A MX2016006561 A MX 2016006561A MX 2016006561 A MX2016006561 A MX 2016006561A
Authority
MX
Mexico
Prior art keywords
seq
chain variable
variable region
antibody
amino acid
Prior art date
Application number
MX2016006561A
Other languages
English (en)
Inventor
Amanda Thuy Tran
Oskar Vilhelmsson Timmermand Pär
Juhani Lamminmäki Urpo
Original Assignee
Fredax Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB1320408.6A external-priority patent/GB2520353A/en
Priority claimed from GB201401973A external-priority patent/GB201401973D0/en
Application filed by Fredax Ab filed Critical Fredax Ab
Publication of MX2016006561A publication Critical patent/MX2016006561A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against enzymes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3069—Reproductive system, e.g. ovaria, uterus, testes, prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1045—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against animal or human tumor cells or tumor cell determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1075—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody the antibody being against an enzyme
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1093—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies
    • A61K51/1096—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody conjugates with carriers being antibodies radioimmunotoxins, i.e. conjugates being structurally as defined in A61K51/1093, and including a radioactive nucleus for use in radiotherapeutic applications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57434—Specifically defined cancers of prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Epidemiology (AREA)
  • Optics & Photonics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • Reproductive Health (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente invención proporciona polipéptidos de anticuerpo con especificidad de unión por la calicreína-2 humana (hK2), en donde el polipéptido de anticuerpo comprende (a) una región variable de la cadena pesada que comprende las secuencias de aminoácidos de SEQ ID NO: 1 y SEQ ID NO: 2 y SEQ ID NO: 3 y/o (b) una región variable de cadena ligera que comprende las secuencias de aminoácidos de SEQ ID NO: 4 y SEQ ID NO: 5 y SEQ ID NO: 6, y en donde la región variable de la cadena pesada y la región variable de la cadena ligera comprenden secuencias de aminoácidos marco de uno o más anticuerpos humanos. La descripción proporciona además el uso de dichos polipéptidos de anticuerpo en el diagnóstico y el tratamiento del cáncer de próstata.
MX2016006561A 2013-11-19 2014-11-19 Anticuerpo anti-calicreina-2 humanizado. MX2016006561A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1320408.6A GB2520353A (en) 2013-11-19 2013-11-19 Antibody polypeptides and uses thereof
GB201401973A GB201401973D0 (en) 2014-02-05 2014-02-05 Antibody polypeptides and uses thereof
PCT/GB2014/053420 WO2015075445A1 (en) 2013-11-19 2014-11-19 Humanised anti kallikrein-2 antibody

Publications (1)

Publication Number Publication Date
MX2016006561A true MX2016006561A (es) 2016-12-12

Family

ID=52114029

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2016006561A MX2016006561A (es) 2013-11-19 2014-11-19 Anticuerpo anti-calicreina-2 humanizado.
MX2021007006A MX2021007006A (es) 2013-11-19 2016-05-19 Anticuerpo anti-calicreina-2 humanizado.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021007006A MX2021007006A (es) 2013-11-19 2016-05-19 Anticuerpo anti-calicreina-2 humanizado.

Country Status (22)

Country Link
US (3) US10100125B2 (es)
EP (2) EP3071595B1 (es)
JP (3) JP6599859B2 (es)
KR (3) KR102442738B1 (es)
CN (1) CN105980404B (es)
AU (3) AU2014351611B2 (es)
BR (1) BR112016011025B1 (es)
CA (1) CA2930493A1 (es)
CY (1) CY1121900T1 (es)
DK (1) DK3071595T3 (es)
ES (1) ES2728515T3 (es)
HR (1) HRP20191095T1 (es)
HU (1) HUE043875T2 (es)
IL (4) IL297678B1 (es)
LT (1) LT3071595T (es)
MX (2) MX2016006561A (es)
PL (1) PL3071595T3 (es)
PT (1) PT3071595T (es)
RS (1) RS58831B1 (es)
RU (1) RU2687163C1 (es)
SI (1) SI3071595T1 (es)
WO (1) WO2015075445A1 (es)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3071595T3 (pl) * 2013-11-19 2019-09-30 Fredax Ab Humanizowane przeciwciało przeciw kalikreinie-2
SG10201808585TA (en) 2014-03-28 2018-11-29 Opko Diagnostics Llc Compositions and methods related to diagnosis of prostate cancer
DK3253800T3 (da) 2015-03-27 2021-05-31 Opko Diagnostics Llc Prostata antigen standarder og bruge deraf
WO2017087826A1 (en) * 2015-11-18 2017-05-26 Memorial Sloan Kettering Cancer Center Systems, methods, and compositions for imaging androgen receptor axis activity in carcinoma, and related therapeutic compositions and methods
JP7105235B2 (ja) 2016-12-01 2022-07-22 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 免疫ｐｅｔイメージングのための放射性標識された抗ｐｄ－ｌ１抗体
BR112019016336A2 (pt) 2017-02-10 2020-03-31 Regeneron Pharmaceuticals, Inc. Conjugado de anticorpo radiorrotulado, método para imageamento de um tecido que expressa lag3 e para tratar um tumor, e, composto.
KR102351556B1 (ko) * 2017-03-30 2022-01-14 프로가스트린 에 캔서스 에스.에이 알.엘. 프로가스트린 결합 분자를 사용하는 전립선암의 검출 및 치료를 위한 조성물 및 방법
US10730944B2 (en) 2017-07-24 2020-08-04 Regeneron Pharmaceuticals, Inc. Anti-CD8 antibodies and uses thereof
JP2022532157A (ja) 2019-05-10 2022-07-13 ヤンセン バイオテツク，インコーポレーテツド 大員環キレータ及びその使用方法
CN114174346A (zh) * 2019-07-26 2022-03-11 詹森生物科技公司 抗hk2嵌合抗原受体(car)
JP2022541332A (ja) * 2019-07-26 2022-09-22 ヤンセン バイオテツク，インコーポレーテツド カリクレイン関連ペプチダーゼ２抗原結合ドメインを含むタンパク質及びその使用
MX2022014938A (es) 2020-05-27 2023-03-06 Janssen Biotech Inc Proteínas que comprenden dominios de unión al antígeno de cd3 y usos de éstas.
CA3189293A1 (en) * 2020-07-17 2022-01-20 Janssen Biotech, Inc. Anti-idiotypic antibodies against anti-klk2 antibodies
TW202233244A (zh) * 2020-11-10 2022-09-01 美商健生生物科技公司 巨環化合物及其使用方法
CN112608365B (zh) * 2020-12-22 2021-07-30 吉林省特医食品生物科技有限公司 一种减轻体重的发酵型小分子肽及其制备方法和应用
CN114790245A (zh) * 2021-01-25 2022-07-26 成都康弘生物科技有限公司 一种抗体及其用途
MX2023008803A (es) 2021-01-27 2023-08-04 Janssen Biotech Inc Inmunoconjugados que comprenden dominios de union al antigeno de la peptidasa 2 relacionada con la calicreina y sus usos.
AU2022282866A1 (en) 2021-05-27 2024-01-18 Janssen Biotech, Inc. Compositions and methods for the treatment of prostate cancer
CA3236851A1 (en) 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and diagnostic uses thereof
WO2023084396A1 (en) 2021-11-09 2023-05-19 Janssen Biotech, Inc. Macrocyclic compounds and methods of making the same
WO2023144723A1 (en) 2022-01-26 2023-08-03 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
SE459005B (sv) 1985-07-12 1989-05-29 Aake Rikard Lindahl Saett att framstaella sfaeriska polymerpartiklar
US5807978A (en) 1995-06-07 1998-09-15 Kokolus; William J. Immunogenic peptides of prostate specific antigen
US6379669B1 (en) 1995-08-04 2002-04-30 Akhouri A. Sinha Targeting of organs by immunoconjugates
CA2192782C (en) 1995-12-15 2008-10-14 Nobuyuki Takechi Production of microspheres
EP0941368A2 (en) 1996-11-14 1999-09-15 Mayo Foundation For Medical Education And Research Method for detection of metastatic prostate cancer
US7053042B1 (en) 1999-07-29 2006-05-30 Samuel Denmeade Activation of peptide prodrugs by hK2
WO2001012218A1 (en) 1999-08-16 2001-02-22 Zonagen, Inc. Methods and materials for the treatment of prostatic carcinoma
FI20002127A0 (fi) 2000-09-27 2000-09-27 Artic Partners Oy Ab Uusi vasta-aine, immunomääritys ja menetelmä eturauhassyövän havaitsemiseksi
EP2277542B1 (en) 2001-06-01 2014-04-16 Cornell Research Foundation Inc. Modified antibodies to prostrate-specific membrane antigen and uses thereof
AU2002362447A1 (en) 2001-10-03 2003-04-14 University Of Rochester Human glandular kallikrein (hk2)-specific monoclonal antibodies that enhance or inhibit the enzymatic activity of hk2
CA2492671C (en) 2002-03-22 2012-04-17 Aprogen, Inc. Humanized antibody and process for preparing same
US7867475B2 (en) 2003-01-31 2011-01-11 Universidad Autonoma De Madrid Immune regulation based on the depletion of CD69+ cells
WO2005094882A1 (en) * 2004-03-03 2005-10-13 Millennium Pharmaceuticals, Inc. Modified antibodies to prostate-specific membrane antigen and uses thereof
US7462697B2 (en) 2004-11-08 2008-12-09 Epitomics, Inc. Methods for antibody engineering
US8663600B2 (en) 2005-02-17 2014-03-04 Diaprost Ab Diagnosis of prostate cancer
EP1851251A2 (en) * 2005-02-18 2007-11-07 Medarex, Inc. Monoclonal antibodies against prostate specific membrane antigen (psma) lacking in fucosyl residues
CL2007002225A1 (es) 2006-08-03 2008-04-18 Astrazeneca Ab Agente de union especifico para un receptor del factor de crecimiento derivado de plaquetas (pdgfr-alfa); molecula de acido nucleico que lo codifica; vector y celula huesped que la comprenden; conjugado que comprende al agente; y uso del agente de un
MX2009005776A (es) 2006-12-01 2009-06-10 Medarex Inc Anticuerpos humanos que se enlazan al cd 22 y sus usos.
JP5523108B2 (ja) * 2006-12-22 2014-06-18 ファディア・アクチボラグ 新規アレルゲンとしての前立腺カリクレイン
WO2010045340A1 (en) * 2008-10-14 2010-04-22 Centocor Ortho Biotech Inc. Methods of humanizing and affinity-maturing antibodies
KR102362358B1 (ko) * 2011-10-28 2022-02-15 프레닥스 에이비 치료제 및 이의 용도
PL3071595T3 (pl) * 2013-11-19 2019-09-30 Fredax Ab Humanizowane przeciwciało przeciw kalikreinie-2

Also Published As

Publication number Publication date
JP6599859B2 (ja) 2019-10-30
KR20230132599A (ko) 2023-09-15
JP2016540503A (ja) 2016-12-28
BR112016011025A8 (pt) 2018-01-30
WO2015075445A1 (en) 2015-05-28
EP3071595B1 (en) 2019-03-20
HUE043875T2 (hu) 2019-09-30
ES2728515T3 (es) 2019-10-25
IL278493B2 (en) 2023-04-01
AU2020207775B2 (en) 2023-06-15
IL311788A (en) 2024-05-01
KR102574537B1 (ko) 2023-09-06
US11230609B2 (en) 2022-01-25
RU2016124229A (ru) 2017-12-25
AU2014351611B2 (en) 2020-04-23
HRP20191095T1 (hr) 2019-09-20
US10100125B2 (en) 2018-10-16
JP2022062048A (ja) 2022-04-19
KR20160096621A (ko) 2016-08-16
CA2930493A1 (en) 2015-05-28
US20160369009A1 (en) 2016-12-22
CN112898431A (zh) 2021-06-04
SI3071595T1 (sl) 2019-08-30
DK3071595T3 (da) 2019-07-01
KR20220020406A (ko) 2022-02-18
RS58831B1 (sr) 2019-07-31
CN105980404B (zh) 2021-01-12
US20190169312A1 (en) 2019-06-06
AU2023222879A1 (en) 2023-09-14
CN105980404A (zh) 2016-09-28
PL3071595T3 (pl) 2019-09-30
EP3071595A1 (en) 2016-09-28
IL245617B (en) 2021-02-28
EP3553088A1 (en) 2019-10-16
IL245617A0 (en) 2016-06-30
LT3071595T (lt) 2019-05-10
IL297678A (en) 2022-12-01
AU2014351611A1 (en) 2016-06-30
AU2020207775A1 (en) 2020-08-06
US20220064333A1 (en) 2022-03-03
CY1121900T1 (el) 2020-10-14
BR112016011025B1 (pt) 2024-01-23
JP2020022470A (ja) 2020-02-13
MX2021007006A (es) 2021-09-08
KR102442738B1 (ko) 2022-09-15
IL278493A (en) 2022-12-01
IL297678B1 (en) 2024-05-01
JP7051777B2 (ja) 2022-04-11
PT3071595T (pt) 2019-06-11
BR112016011025A2 (pt) 2017-12-05
RU2687163C1 (ru) 2019-05-07

Similar Documents

Publication Publication Date Title
MX2021007006A (es) Anticuerpo anti-calicreina-2 humanizado.
ZA202211057B (en) Anti-trem2 antibodies and methods of use thereof
MX2017001401A (es) Constructos de anticuerpos de cadena sencilla biespecifica especificos para especies cruzadas optimizadas.
EA201592006A1 (ru) Новые биспецифические связывающие молекулы с противоопухолевой активностью
NZ629553A (en) Anti-big-endothelin-1 (big-et-1) antibodies and uses thereof
PE20181054A1 (es) Anticuerpos anti-cd19 humano humanizados y metodos de utilizacion
MX355268B (es) Anticuerpos de peptido beta amiloide anti-n3pglu y usos de los mismos.
JOP20190103B1 (ar) شدفة Fab جديدة لجسم مضاد ضد MUC1 بشري
NZ703653A (en) Anti-fap antibodies and methods of use
MX2018009011A (es) Anticuerpos anti receptor 1 transmembrana de tirosina-proteina cinasa (ror1) y usos de los mismos.
NZ601271A (en) Cd127 binding proteins
NZ594682A (en) Fully human antibodies specific to cadm1
MX347829B (es) Molécula fv de unión a antígeno multivalente.
NZ611428A (en) Novel modulators and methods of use
MX2015008623A (es) Anticuerpos que se unen al ligando 1a tipo tnf y sus usos.
MX2016004579A (es) Proteinas de union del miembro 1 de la familia de transmembrana 4 l-seis (tm4sf1) y metodos de uso de las mismas.
NZ595792A (en) Antibodies specific to cadherin-17
MX2019010397A (es) Seleccion de pacientes de cefalea que responden a anticuerpos dirigidos contra el peptido relacionado con el gen de la calcitonina.
NZ610091A (en) Antibodies
MX2017000615A (es) Anticuerpo anti-tie 2 humano novedoso.
MX2014001766A (es) Anticuerpos de neuregulina y sus usos.
EA201790341A1 (ru) Анти-ск8 антитела для применения в лечении рака
MX2016008520A (es) Anticuerpo bdca-2 antihumano novedoso.
MX2015002465A (es) Anticuerpos monoclonales para mejorar o inhibir factor de crecimiento 1 similar a insulina (igf-1).
EA201391453A1 (ru) Новое антитело против рецептора il-23 человека